We are live on ! Find out more
ISEE

IVERIC bio, Inc. Common Stock

Delisted

ISEE was delisted on the 10th of July, 2023.

225 hedge funds and large institutions have $3.12B invested in IVERIC bio, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 88 increasing their positions, 62 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more funds holding in top 10

Funds holding in top 10: 1019 (+9)

42% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 62

37% more call options, than puts

Call options by funds: $35.3M | Put options by funds: $25.6M

37% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 38

35% more capital invested

Capital invested by funds: $2.31B → $3.12B (+$805M)

6% more funds holding

Funds holding: 213225 (+12)

Holders
225
Holders Change
+12
Holders Change %
+5.63%
% of All Funds
3.62%
Holding in Top 10
19
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+90%
% of All Funds
0.31%
New
52
Increased
88
Reduced
62
Closed
38
Calls
$35.3M
Puts
$25.6M
Net Calls
+$9.61M
Net Calls Change
-$105M
Name Holding Trade Value Shares
Change
Change in
Stake
FCM
26
Farallon Capital Management
California
$31.3M +$3.09M +145,000 +11%
Invesco
27
Invesco
Georgia
$30.2M +$21.5M +1,008,383 +250%
American Century Companies
28
American Century Companies
Missouri
$28.5M +$28.4M +1,331,374 New
OCA
29
Octagon Capital Advisors
New York
$27.4M +$27.3M +1,278,000 New
Goldman Sachs
30
Goldman Sachs
New York
$27.3M +$5.85M +274,126 +27%
Northern Trust
31
Northern Trust
Illinois
$27.1M +$3.5M +163,795 +15%
PVI
32
Pura Vida Investments
New York
$25.3M +$4.43M +207,545 +21%
CS
33
Candriam SCA
Luxembourg
$24.3M +$11.4M +533,000 +88%
Ameriprise
34
Ameriprise
Minnesota
$23.4M +$18.2M +850,515 +350%
MB
35
MPM BioImpact
Massachusetts
$22.7M +$207K +9,688 +0.9%
TCM
36
TimesSquare Capital Management
New York
$21.7M +$21.6M +1,011,640 New
AG
37
Artal Group
Luxembourg
$21.4M +$5.34M +250,000 +33%
Charles Schwab
38
Charles Schwab
California
$20.6M +$2.99M +140,208 +17%
PHS
39
PFM Health Sciences
California
$19.6M +$14.1M +661,273 +258%
KCM
40
Kingdon Capital Management
New York
$18.3M +$18.2M +853,000 New
Balyasny Asset Management
41
Balyasny Asset Management
Illinois
$18.1M -$17.9M -839,924 -50%
APM
42
Avidity Partners Management
Texas
$18M +$17.9M +838,407 New
BC
43
Boxer Capital
California
$17.7M +$17.6M +825,000 New
GPP
44
Great Point Partners
Connecticut
$17.7M +$17.6M +825,000 New
RI
45
RTW Investments
New York
$17.6M -$59.8M -2,803,712 -77%
D.E. Shaw & Co
46
D.E. Shaw & Co
New York
$17.4M +$15.5M +726,378 +839%
SB
47
Samsara BioCapital
California
$17.3M
Skandinaviska Enskilda Banken (SEB)
48
Skandinaviska Enskilda Banken (SEB)
Sweden
$16.9M -$141K -6,584 -0.8%
DCM
49
Driehaus Capital Management
Illinois
$16.8M +$667K +31,232 +4%
EA
50
Emerald Advisers
Pennsylvania
$16.3M -$4.33M -202,863 -21%

ISEE Hedge Fund Activity: Q4 2022 in Review

225 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q4 2022, worth a combined $3.12B — up 35% from $2.31B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new ISEE positions and 38 closed out — a net gain of 14 holders — while 88 added to existing stakes and 62 trimmed.

The largest buyer was Vanguard Group, adding an estimated $86.1M. The largest seller was Janus Henderson Group, cutting an estimated $121M.

  • 225 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q4 2022, up from 213 in Q3 2022.
  • Funds reported $3.12B of IVERIC bio, Inc. Common Stock stock for Q4 2022, up 35% quarter-over-quarter.
  • 52 funds opened new IVERIC bio, Inc. Common Stock positions in Q4 2022 and 38 closed out, a net change of +14 holders.
  • The largest IVERIC bio, Inc. Common Stock buyer in Q4 2022 was Vanguard Group, an estimated $86.1M added.
  • The largest IVERIC bio, Inc. Common Stock seller in Q4 2022 was Janus Henderson Group, an estimated $121M sold.

Based on aggregated 13F filings for Q4 2022.